BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...CATEGORY: MusculoskeletalINDICATION: OsteoarthritisInhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2...
...in healthy cartilage. In a mouse fibroblast cell line, an siRNA or an shRNA targeting ROR2...
...enzymes ADAMTS4 and ADAMTS5. In a mouse model of osteoarthritis induced by menisco-ligament injury, the anti-ROR2...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

With its $137 million series B round Wednesday, VelosBio became the 50th biotech this year to raise a venture round topping the $100 million mark (see "Venture Megarounds Tracking to New Record” ). It is...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Apr 11, 2019
Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

WuXi Biologics will manufacture NBE-Therapeutics’ lead antibody-drug conjugate, NBE-002, for use in clinical trials worldwide. NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020. NBE-Therapeutics declined to disclose details. WuXi Biologics...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...K member 1 (NKG2D; KLRK1; CD314) Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) CYAD-01 Colorectal cancer Ph I/II Receptor tyrosine kinase-like orphan receptor 2 (ROR2)...
BioCentury | Dec 7, 2018
Emerging Company Profile

ADCendo: entering tumors via MRC2

...against AXL receptor tyrosine kinase (AXL; UFO), and BioAtla LLC has BA3021, an ADC against receptor tyrosine kinase-like orphan receptor 2 (ROR2)...
BioCentury | May 23, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; brain cancer; solid tumors Mouse studies suggest liposomal nanoparticles loaded with immunomodulatory agents could enhance the efficacy of CAR T therapies to treat solid cancers. The liposomal nanoparticles are coated with an...
Items per page:
1 - 10 of 43